Dimerix Ltd (ASX: DXB) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Dimerix Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$209.19 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
557.03 million
Earnings per share
-0.038
Dividend per share
N/A
Year To Date Return
97.56%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Dimerix Ltd (ASX: DXB)
Latest News
Share Gainers
These 3 ASX Healthcare shares have soared over 10% today
Healthcare Shares
Dimerix (ASX:DXB) share price soars 9% on COVID-19 news
Healthcare Shares
The Dimerix (ASX:DXB) share price is up 3% on Thursday
Share Fallers
Dimerix (ASX:DXB) share price down 10% after prospectus issued
Healthcare Shares
Dimerix (ASX:DXB) share price rockets 50% on capital raise and results
Share Gainers
Why the Dimerix (ASX:DXB) share price is rocketing higher
Share Market News
Why the Dimerix (ASX:DXB) share price is up today
Share Market News
Why the Dimerix (ASX:DXB) share price is surging 6% higher today
Share Market News
Why the Dimerix (ASX:DXB) share price has plunged 63% today
Growth Shares
3 ASX shares that could make you rich
Speculative
Dimerix share price doubles after being included in global COVID-19 study
❮2
DXB ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Dimerix Ltd
A clinical stage drug discovery and development company. The operational headquarters of the company are in Melbourne, where Dimerix's lead clinical program is a Phase 2 study in Chronic Kidney Disease, DMX-200
DXB Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 15 Nov 2024 | $0.38 | $0.00 | 0.00% | 1,548,033 | $0.38 | $0.39 | $0.37 |
| 14 Nov 2024 | $0.38 | $-0.02 | -5.13% | 2,057,685 | $0.39 | $0.39 | $0.37 |
| 13 Nov 2024 | $0.39 | $0.00 | 0.00% | 716,915 | $0.39 | $0.39 | $0.38 |
| 12 Nov 2024 | $0.39 | $0.00 | 0.00% | 1,151,070 | $0.39 | $0.40 | $0.38 |
| 11 Nov 2024 | $0.39 | $-0.02 | -4.94% | 797,631 | $0.41 | $0.41 | $0.39 |
| 08 Nov 2024 | $0.41 | $0.03 | 8.00% | 1,624,946 | $0.37 | $0.41 | $0.37 |
| 07 Nov 2024 | $0.38 | $-0.01 | -2.60% | 1,820,717 | $0.39 | $0.39 | $0.37 |
| 06 Nov 2024 | $0.39 | $0.01 | 2.63% | 709,301 | $0.39 | $0.39 | $0.39 |
| 05 Nov 2024 | $0.38 | $-0.01 | -2.60% | 615,803 | $0.39 | $0.40 | $0.38 |
| 04 Nov 2024 | $0.39 | $-0.01 | -2.56% | 949,797 | $0.40 | $0.40 | $0.38 |
| 01 Nov 2024 | $0.39 | $-0.01 | -2.50% | 934,638 | $0.40 | $0.41 | $0.39 |
| 31 Oct 2024 | $0.40 | $-0.01 | -2.47% | 1,067,424 | $0.43 | $0.43 | $0.40 |
| 30 Oct 2024 | $0.41 | $0.01 | 2.53% | 1,875,770 | $0.41 | $0.42 | $0.40 |
| 29 Oct 2024 | $0.40 | $-0.04 | -9.30% | 2,356,612 | $0.43 | $0.43 | $0.40 |
| 28 Oct 2024 | $0.43 | $0.01 | 2.38% | 1,678,934 | $0.44 | $0.44 | $0.41 |
| 25 Oct 2024 | $0.42 | $0.01 | 2.44% | 1,151,174 | $0.42 | $0.43 | $0.41 |
| 24 Oct 2024 | $0.41 | $-0.02 | -4.71% | 2,002,430 | $0.43 | $0.43 | $0.41 |
| 23 Oct 2024 | $0.43 | $-0.03 | -6.67% | 3,063,644 | $0.45 | $0.45 | $0.43 |
| 22 Oct 2024 | $0.45 | $-0.01 | -2.20% | 792,047 | $0.45 | $0.46 | $0.44 |
| 21 Oct 2024 | $0.46 | $0.01 | 2.22% | 1,390,772 | $0.46 | $0.47 | $0.45 |
| 18 Oct 2024 | $0.45 | $-0.04 | -8.16% | 2,375,770 | $0.49 | $0.49 | $0.45 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 21 Oct 2024 | Mark Diamond | Issued | 300,000 | $110,148 |
Employee Share Ownership Plan. Black-Scholes valuation
|
| 21 Oct 2024 | Hugh Alsop | Issued | 300,000 | $110,148 |
Employee Share Ownership Plan. Black-Scholes valuation
|
| 21 Oct 2024 | Nina Webster | Issued | 1,500,000 | $550,740 |
Employee Share Ownership Plan. Black-Scholes valuation
|
| 21 Oct 2024 | Sonia Poli | Issued | 300,000 | $110,148 |
Employee Share Ownership Plan. Black-Scholes valuation, as per announcement on 25-10-2024
|
| 21 Oct 2024 | Clinton Snow | Issued | 300,000 | $110,148 |
Employee Share Ownership Plan. Black-Scholes valuation
|
| 30 Jul 2024 | Hugh Alsop | Expiry | 167,202 | $72,732 |
Options expired.
|
| 25 Jul 2024 | Sonia Poli | Exercise | 167,202 | $66,880 |
Exercise of options.
|
| 25 Jul 2024 | Sonia Poli | Buy | 167,202 | $66,880 |
Exercise of options.
|
| 10 Apr 2024 | Sonia Poli | Expiry | 37,500 | $11,437 |
Options expired. As per announcement on 03-06-2024
|
| 10 Apr 2024 | Nina Webster | Expiry | 25,000 | $7,625 |
Options expired.
|
| 27 Mar 2024 | Nina Webster | Buy | 33,000 | $10,230 |
On-market trade.
|
| 26 Mar 2024 | Sonia Poli | Exercise | 12,501 | $1,575 |
Exercise of options.
|
| 26 Mar 2024 | Sonia Poli | Issued | 12,501 | $1,575 |
Exercise of options.
|
| 19 Mar 2024 | Nina Webster | Exercise | 93,750 | $11,812 |
Exercise of options.
|
| 19 Mar 2024 | Nina Webster | Issued | 93,750 | $11,812 |
Exercise of options.
|
| 01 Dec 2023 | Nina Webster | Issued | 2,052,956 | $282,675 |
Employee Share Ownership Plan. Black-Scholes valuation
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Mark P Diamond | Non-Executive Director | Dec 2023 |
Mr Diamond is a senior pharmaceutical executive with more than thirty years within the pharmaceutical and biotechnology industries. Prior to his time at Antisense, Mark served in senior product and business development roles at Faulding Pharmaceuticals (now Pfizer) within their US, European and international pharmaceutical operations. Mark is currently a Senior Advisor for Boston based Global Investment Bank, Locust Walk and Biotech Advisor for Spark Plus, a Corporate Advisory specialist firm in Singapore.
|
| Mr Hugh Alsop | Non-Executive Director | May 2017 |
Mr Alsop is an executive with experience in international business development, partnering, drug development and leadership of scientific teams. Hugh is currently CEO of Kinoxis Therapeutics, a private company developing novel therapeutics for substance use disorders and other neurological conditions. Prior to Kinoxis, Hugh was CEO of venture-backed private company Hatchtech, where he was responsible for several drug development programs for the international markets. Hugh is also a non-Executive director of private companies Servatus Ltd, Eflare Corporation Pty Ltd, Avalyn Australia Pty Ltd, AnaptysBio Pty Ltd and Lassen Therapeutics1 Pty Ltd.
|
| Ms Nina Webster | Chief Executive OfficerManaging Director | Aug 2018 |
Ms Webster has experience in the pharmaceutical industry, with leadership roles across strategy, commercialization, intellectual property, scientific and operational aspects of product development. Nina worked in large Pharma, Wyeth Pharmaceuticals (UK). Nina is also a Non-Executive Director of Linear Clinical Research Limited and SYNthesis BioVentures Pty Ltd.
|
| Dr Sonia Maria Poli | Non-Executive Director | Jul 2015 |
Dr Poli is a R&D professional with 20 years international experience in large and small pharmaceutical companies. Sonia is currently serving as advisor for several late-stage drug development projects approaching market authorization. Sonia was formerly Executive Manager at AC Immune,Nasdaq listed company, and Chief Scientific Officer at Minoryx and Addex Therapeutics and she has previously worked within Swiss Stock Exchange listed companies Hoffman la Roche.
|
| Mr Clinton Snow | Non-Executive Director | May 2023 |
Mr Snow has 20 years of experience as a technology leader with a focus in engineering management, project delivery, risk management and assurance. Clinton is providing advisory services to a family office with multiple Australian biotech investments.
|
| Mr Hamish George | Chief Financial OfficerCompany Secretary | May 2019 |
-
|
| Robert Shepherd | Chief Commercialization Officer |
-
|
|
| Hamish George | Chief Financial OfficerCompany Secretary |
-
|
|
| David Fuller | Chief Medical Officer |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Mr Peter Fletcher Meurs | 35,572,412 | 6.46% |
| Skiptan Pty Ltd <P&M Meurs Family A/C> | 29,732,028 | 5.40% |
| J P Morgan Nominees Australia Pty Limited | 17,807,381 | 3.23% |
| HSBC Custody Nominees (Australia) Limited | 11,098,120 | 2.02% |
| Precision Opportunities Fund Ltd <Investment A/C> | 10,080,875 | 1.83% |
| Citicorp Nominees Pty Limited | 9,836,824 | 1.79% |
| National Nominees Limited | 8,197,234 | 1.49% |
| Bavaria Bay Pty Ltd | 7,316,992 | 1.33% |
| BNP Paribas Noms Pty Ltd | 6,041,838 | 1.10% |
| Skiptan Pty Ltd <P&M Meurs Family A/C> i | 5,928,514 | 1.08% |
| Mr Richard Stanley De Ravin | 5,485,000 | 1.00% |
| Yodambao Pty Ltd <Yodambao Investment A/C> | 5,480,732 | 1.00% |
| Mrs Melinda Jane Coates & Mr Andrew Joseph Coates <Melindajcoates Superfund A/C> | 5,450,000 | 0.99% |
| Mrs Julie Maree Scott | 4,500,000 | 0.82% |
| Mr Philip Robert Scott | 4,500,000 | 0.82% |
| Mr Peter Fletcher Meurs i | 4,446,552 | 0.84% |
| Mr Andrew Joseph Coates & Mrs Melinda Jane Coates <Aj & Mj Coates S/F A/C> | 4,306,000 | 0.78% |
| Mr Zhaoyang Bi & Mrs Feifei Cheng <Bi&Cheng Superfund A/C> | 3,800,000 | 0.69% |
| BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> | 3,317,351 | 1.09% |
| Mrs Gwen Murray Pfleger <Pfleger Family A/C> | 3,158,982 | 0.57% |
